BRANFORD, Conn., Dec. 11, 2017 /PRNewswire/ -- IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology and the immune-based cancer treatment revolution, announced today that its IsoCode Chip and IsoLight Platform won the 2017 Fierce Innovation Award for Technology Innovation in the life sciences industry.
The IsoCode Chip and IsoLight Platform are a simple, integrated solution for detecting cellular responses at the single-cell resolution. The next-generation technology can capture a previously unseen 42 different secreted functional proteins per cell, across thousands of single cells simultaneously. Through IsoPlexis' bioinformatics tools, the system enables researchers to generate a precise functional patient profile to help predict, identify and understand complex patient response to cancer immunotherapies.
"It is an honor to receive this award from the publishers of FierceBiotech and FiercePharma," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "Clinical researchers at leading academic and biopharmaceutical labs are using IsoPlexis technology to better understand how to use the human immune system in the fight against cancer, and we're proud that our technology is helping to advance more personalized and more potent immunotherapies for patients that need them the most."
The Fierce Innovation Awards: Life Sciences Edition is presented annually by the publishers of FierceBiotech and FiercePharma to highlight outstanding innovations in different categories, including technology, that are driving improvements and transforming the life sciences field. An expert panel of judges reviewed all submissions and scored them based on their potential to make the greatest impact for biotech and pharmaceutical companies. The Technology Innovation category highlights products and services that are using innovative technology solutions to better serve the life sciences industry and promote innovation.
For more information about the Fierce Innovation Awards: Life Sciences and the full list of categories and winners, visit: https://questex-lifesciences2017.secure-platform.com/a/organizations/main/home.
IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single cell level, IsoPlexis' original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email email@example.com.
SOURCE IsoPlexis Corporation